Akebia Therapeutics Inc.
AKBA
Get informed when a big investor buys or sells
+ FollowMarket Cap$245.64M
Close$
$-2.55
360.3% downside
Current Fair Value
360.3% downsideOvervalued by 360.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $245.64 Million |
|---|---|
| Enterprise Value | $150.23 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.02 |
| Beta | 0.24 |
| Outstanding Shares | 269,602,747 |
Return
| Return on Equity | -118.58% |
|---|---|
| Return on Assets | -8.48% |
| Return on Invested Capital | -8.37% |
Valuation & Multiples
| P/E Ratio | -8.48 |
|---|---|
| PEG | 0.23 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.69 |
| Enterprise Value to EBIT | -9.51 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.4 |
| Debt to Equity | 2.4 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.03
Average shareholder expectationRevenue Estimate
$48.85 M
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.03
Average shareholder expectationRevenue Estimate
$46.94 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.1427▲ 46.78% |
|---|---|
| Total Calls | 393,800▼ 24.02% |
| Total Puts | 450,000▲ 28.64% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 40.90%▲ 2.81% |
|---|---|
| Total Invested | $125.80M▼ 11.04% |
| Investors Holding | 1770% |
ESG Score
No data
About Akebia Therapeutics Inc.
CEO: John Butler